Dr. Hassan Hamdan

I treat EBOO as a clinical procedure that belongs inside a wider, supervised plan rather than as a one-off. The most important part is the assessment beforehand: I review your history and medications, and I am candid when EBOO is not the right choice. When it is appropriate, I prefer to use it alongside, not instead of, the rest of a longevity protocol, and to keep expectations measured and evidence-led.

Plasmapheresis is a procedure I approach conservatively. I want a clear clinical rationale before recommending it, and I prefer to set expectations plainly: it is performed under supervision, suitability is assessed individually, and it sits within a wider longevity plan rather than standing alone. If it is not the right option, I will say so.

I treat NAD+ as one input within a longevity plan, not a standalone fix. We start with your history, set the dose conservatively, and give the infusion slowly because the rate matters more than the total. I am candid about what the evidence does and does not show, and I would rather a patient understand that than expect a dramatic result.